Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

SpeedWeed

JULY 23, 2021

Denver is expanding Alzheimer’s research through the efforts of local company MedPharm. . The company plans to move forward with research efforts through a special Schedule I Researcher Licenses given specifically to the company by the Drug Enforcement Administration. Denver Company Moves Forward with Research License .

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

CannaMD

AUGUST 8, 2020

Researchers believe cannabis contains over 100 unique chemical compounds! Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential.

CBD 105

CBD DEA Research and Development Hemp 105

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ).

Therapy 101

Therapy Legalization Chronic Pain DEA 101

Cannabis Law Report

JULY 9, 2021

Further, numerous private companies have begun to research psychedelic therapy and develop new pharmaceutical compounds derived from psychedelic substances. In June 2021, similar measures were passed in Connecticut and Texas, where medical research on psilocybin is now also legal on a statewide level.

Law 81

Law Therapy Clinical Trials Research and Development 81

Veriheal

AUGUST 31, 2020

We are humbled to introduce you to them and their exceptional ideas, ranging from community grassroots mental health efforts designed to empower historically vulnerable communities of color, to research plans for identifying strain specific genetics. Veriheal’s Innovation in Cannabis Scholarship 2020 Winners . Nishtha Tripathi.

Research and Development 119

Research and Development Education Agriculture Patients 119

MedicalJane

JUNE 29, 2018

On June 26, 2018, the FDA granted approval of Epidiolex, a cannabidiol (CBD) oral solution, to GW Research Ltd (GW). Use of CBD in seizure prevention is well-documented with research ; and now, after conducting its own trials, the FDA appears to agree. Clinical trials show that Epidiolex significantly reduces seizure frequency.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

MARCH 18, 2022

Husch Blackwell has launched its Psychedelics and Emerging Therapie s team, an interdisciplinary, cross-office group of lawyers capable of addressing the challenges faced by innovators that seek to research, develop and commercialize novel therapies based on psychedelic drugs. Steve Levine.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

Cannabis Law Report

APRIL 21, 2022

MAPS and MAPS PBC have developed the first validated commercial synthetic process for producing multi-kilogram batches of MDMA under current Good Manufacturing Practices. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment. The full statement. Nair, Ph.D., Berra Yazar-Klosinski, Ph.D.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

SpeedWeed

AUGUST 11, 2021

According to Dr. Sue Sisley, President of the Scottsdale Research Institute and longtime cannabis researcher, this new study is sorely needed in the community. Veterans are demanding objective cannabis drug development research, and the state of Michigan is fulfilling our collective obligation to our beloved Veteran community.”.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

APRIL 8, 2022

as a non-profit organization to fulfill the need to broaden psychedelic research, therapy, and develop legal options for psychedelic medicine. Rick Doblin founded MAPS as an official 501(c)(3) non-profit research organization on April 8, 1986. Later that year, Doblin sued the DEA for the first time.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

OCTOBER 5, 2021

The drug has previously been used with some success in clinical trials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience. The team now plan to investigate the effect of music on the brain while under the influence of psilocybin using an MRI scanner.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

SEPTEMBER 20, 2019

The sale will greatly reduce the current and future burn rate of the company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the U.S.

Clinical Trials 40

Clinical Trials Research and Development DEA Business 40

Cannabis Law Report

APRIL 13, 2022

North American Industry Leader in Psychedelic Therapy and Research. Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Watch Video: The Press Release. NEWS PROVIDED BY. Numinus Wellness Inc. .

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. BUFFALO, N.Y. , Aug. Tweet this.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Veriheal

JUNE 24, 2021

health official reportedly slammed “ongoing federal restrictions that are inhibiting research into marijuana”. The Senator stated that the NIH has been reporting on “potentially promising peer-reviewed clinical research” and asked for an update on how the NIH was planning to proceed and navigate issues. .

Research and Development 52

Research and Development Clinical Trials Treatment Access 52

The Cannigma

MAY 1, 2023

Named because it is the result of the joining two different chemical types – a ketone and an amine, ketamine was developed in 1962 as an alternative dissociative anesthetic drug to the potently hallucinogenic phencyclidine, known more commonly as PCP. It was becoming clear that another class of anesthetics was needed.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

JUNE 4, 2021

Dr. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career. Dr. Titus developed several prominent cannabis companies, including HempMeds, KannaLife Sciences Inc, and Kannaway, LLC.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Weedistry

MARCH 7, 2019

Marijuana Fights Cancer and Helps Manage Side Effects, Researchers Find. She had been screening brain cancer cells because they grow faster than normal cell lines and thus are useful for research purposes. The ID -1 gene is active during human embryonic development, after which it turns off and stays off.

THC 40

THC CBD Clinical Trials Research and Development 40

Cannabis Law Report

APRIL 1, 2019

It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Cannabis Law Report

JULY 12, 2019

By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). Things seemed to go well in animal trials using URB597. (21)

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

JANUARY 11, 2019

Accordingly, the Drug Enforcement Administration (DEA) no longer has any claim to interfere with the interstate commerce of hemp products, so as long as the THC level is at or below 0.3%. While the DEA is now officially out of the hemp regulation business, the U.S. The FDA’s position on CBD is unsettled and unsupported by law.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business 52

Business Policy Clinical Trials Research and Development 52

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. These cannabis products are used by researchers in the U.S.

DEA 92

DEA Research and Development Cultivation Supply Chain 92

Cannabis Law Report

MAY 29, 2022

Earlier this month, Senators Brian Schatz (D-HI) and Cory Booker (D-NJ) sent a letter to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) urging both agencies to advance research on the therapeutic effects of psychedelic drugs. [1] Recent Regulatory Developments. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

FEBRUARY 28, 2022

In the past two decades, pioneering research has rekindled interest in the therapeutic use of psychedelic substances such as psilocybin, ibogaine, and dimethyltryptamine (DMT). Indigenous communities have used them for centuries, and researchers studied them in the 1950s and ‘60s. Glenn Cohen & Mason Marks. 20 February 2022.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ).

Legalization 54

Legalization Therapy Chronic Pain DEA 54

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. And time was an issue, since her research projects involved suicidal combat veterans with PTSD and stage 4 cancer patients who didn’t have long to live. Dr. Sue Sisley.

DEA 219

DEA Research and Development Clinical Trials Patients 219

SpeedWeed

DECEMBER 28, 2018

There’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval. But there’s nothing to justify the sky-high price (about $90 per day) beyond the cost of research and development to win FDA approval and Big Pharma’s insatiable thirst for profits.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

Canna Law Blog

NOVEMBER 6, 2021

Once off-limits because of federal prohibition, a trickle of research from the 1990s has grown into a stream. But despite increasing acceptance by the public, and commercial investment in psychedelic therapies, aging federal laws stem the flow of vital research. Research was permitted in the mid-20th century, until the law stepped in.

Clinical Trials 98

Clinical Trials DEA Research and Development Therapy 98